Showing results (71-80 of 349) with videos related to
Sort By:
Pageof 35
Clinical Genitourinary Cancer|December 6, 2021
Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder CancerMichael Xiang, Albert J Chang, Karim Chamie, et al.Clinical Genitourinary Cancer|March 8, 2020
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell CarcinomaAndreas Varkaris, Wenxin Xu, Roger B Davis, et al.BJU International|February 16, 2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancerShuchi S Pandya, James W Mier, David F McDermott, et al.JCO Precision Oncology|June 17, 2024
ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature ReviewNikhita Kathuria-Prakash, Lidia P Lopez, Steven Raman, et al.Journal of the Endocrine Society|June 10, 2024
The Effect of Apalutamide on Thyroid Function in Prostate Cancer PatientsClare Moffatt, Melissa G Lechner, Trevor E Angell, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2023
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center AnalysisVishnu Murthy, Andrei Gafita, Pan Thin, et al.Urologic Oncology|August 12, 2020
"Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinomaAlexandra Drakaki, Allan Pantuck, Shivani K Mhatre, et al.World Journal of Urology|January 5, 2018
Trends in urinary diversion after radical cystectomy for urothelial carcinomaKinan Bachour, Izak Faiena, Amirali Salmasi, et al.The Journal of Urology|May 9, 2017
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical TrialsAndrew T Lenis, Nicholas M Donin, David C Johnson, et al.Frontiers in Endocrinology|November 29, 2023
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitusRobin Hilder, Karen Tsai, Zoe Quandt, et al.Pageof 35